Why CervoMed Inc.’s neflamapimod findings may reshape biomarker-driven trials in dementia with Lewy bodies
CervoMed Inc. reveals neflamapimod MRI data in DLB. Discover how biomarker-driven trials could reshape neurodegeneration drug development.
Pharma & Biotech
Medical Devices & Diagnostics
Can MRI body scans redefine preventive care? AMRA expands into Dutch market with Prescan
AMRA and Prescan launch a first-in-Netherlands MRI scan to assess fat and muscle composition. Learn how this could redefine early disease detection in Europe.